6108.HK Stock Analysis
61
Uncovered
New Ray Medicine International Holding Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
New Ray Medicine International Holding Ltd. is an investment company, which engages in the distribution and trading of pharmaceutical products. The company is headquartered in Hangzhou, Zhejiang and currently employs 26 full-time employees. The company went IPO on 2013-10-25. The firm operates its business through four segments. The Injection Drugs segment is engaged in the trading of injection drugs. The Capsule and Granule Drugs segment is engaged in the trading of capsule and granule drugs. The Tablet Drugs segment is engaged in the trading of tablet drugs. The Others segment is engaged in the trading of miscellaneous types of goods and drugs.